TXG Gains From Proteintech Deal, Expands Multiomics Capabilities

10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.

Zacks Investment Research • Jun 10, 2026

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.

PRNewsWire • Jun 9, 2026

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • Jun 4, 2026

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026

10x Genomics Q1 Earnings Call Highlights

10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.

MarketBeat • May 9, 2026

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up

TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.

Zacks Investment Research • May 8, 2026

10x Genomics Reports First Quarter 2026 Financial Results

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.

PRNewsWire • May 7, 2026

10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 7, 2026

10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.

Zacks Investment Research • May 7, 2026